Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
84808 trials found · Page 37 of 4241
-
Dual-Target CAR-T therapy offers new hope for Hard-to-Treat myeloma
Disease control Recruiting nowThis study aims to investigate the efficacy and safety of CD19/BCMA CAR-T cells in treating relapsed/refractory multiple myeloma.
Phase: NA • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Apr 22, 2026 16:00 UTC
-
Breakthrough trial aims to stop deadly skin cancer from coming back
Disease control Not yet recruitingAllogeneic hematopoietic stem cell transplantation (alloHSCT) showed efficacy in advanced-stage, high-risk, treatment sensitive cutaneous T-cell lymphomas (CTCL) in a prospective, propensity score-matched controlled study (CUTALLO) published by our group in the Lancet in 2023. Ne…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Apr 15, 2026 16:14 UTC
-
Virus vs. superbug: experimental treatment targets deadly hospital pneumonia
Disease control Not yet recruitingThe purpose of this study is to systematically evaluate the efficacy and safety of bacteriophage cocktail therapy in patients with ventilator-associated pneumonia caused by Gram-negative bacterial infections.
Phase: NA • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Apr 23, 2026 07:14 UTC
-
Race against time: experimental stroke treatment extends critical window when surgery Isn't available
Disease control Not yet recruitingThe goal of this clinical trial is to learn if tenectplase works to acute ischemic stroke (AIS) with onset 4.5-9 hours. It will also learn about the safety of tenectplase in AIS with onset 4.5-9 hours. The main question it aims to answer is: Does tenectplase improve the 90-days f…
Phase: PHASE3 • Sponsor: The First Affiliated Hospital of University of Science and Technology of China • Aim: Disease control
Last updated Apr 13, 2026 20:16 UTC
-
Florida launches AI cancer breakthrough trial: custom treatments for tough cases
Disease control Recruiting nowThrough this study funded by the Florida Cancer Innovation Fund, First Ascent will demonstrate state-wide feasibility of providing xDRIVE Functional Precision Medicine + Artificial Intelligence platform by assessing patient clinical benefit and health economics impacts. As this i…
Phase: NA • Sponsor: First Ascent Biomedical Inc. • Aim: Disease control
Last updated Apr 14, 2026 13:09 UTC
-
5-Day brain zap could lift postpartum depression fog
Disease control Recruiting nowThis study is a large, multi-site clinical trial testing whether Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), a fast-acting form of repetitive transcranial magnetic stimulation (rTMS), can more effectively reduce symptoms of postpartum depression (PPD) compar…
Phase: NA • Sponsor: Magnus Medical • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Brain-Delivered gene therapy offers hope for devastating childhood disorder
Disease control Recruiting nowThe goal of this first in human, phase I/II clinical trial is to evaulate the safety, tolerability, and preliminary efficacy of AAV9 mediated gene replacement therapy (Urbagen) in paediatric patients with CTNNB1 neurodevelopmental disorder. The main questions it aims to answer ar…
Phase: PHASE1, PHASE2 • Sponsor: CTNNB1 Foundation • Aim: Disease control
Last updated Apr 15, 2026 16:15 UTC
-
New MS drug enters final testing phase to control disease activity
Disease control Recruiting nowThe aim of this study is to compare the efficacy, safety profile, pharmacokinetics, pharmacodynamics, and immunogenicity of BCD-281 and the reference drug in subjects with relapsing multiple sclerosis.
Phase: PHASE3 • Sponsor: Biocad • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New drug trial aims to save lives from severe breathing crisis
Disease control Recruiting nowTo evaluate the efficacy, safety and tolerability of STSA-1002 injection in patients with acute respiratory distress syndrome
Phase: PHASE3 • Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Apr 17, 2026 16:12 UTC
-
New Triple-Threat treatment trial for advanced liver cancer
Disease control Recruiting nowThis is a multi-center randomized phase III clinical study of first-line Camrelizumab and Apatinib with or without intravenous FOLFOX Chemotherapy for Advanced Hepatocellular Carcinoma (HCC).
Phase: PHASE3 • Sponsor: Linhui Peng • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC
-
New targeted drug battles standard chemo in advanced lung cancer trial
Disease control Recruiting nowTROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable genomic alterations (AGA).
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 20, 2026 16:14 UTC
-
Breakthrough trial offers new hope for Tough-to-Treat breast cancer
Disease control Recruiting nowThis is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participants nor the trial doctors will know which o…
Phase: PHASE3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Apr 23, 2026 07:14 UTC
-
Experimental immune cell therapy offers hope for tough blood cancers
Disease control Not yet recruitingA Clinical Study to Explore the Safety, Efficacy and Cellular Metabolic Kinetics of CT1194D CAR-T Cells Injection in Patients with Relapsed/Refractory B-Cell Neoplasms
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC
-
New Two-Drug attack on advanced lung cancer enters final testing phase
Disease control Recruiting nowThis study is a randomized, controlled, open-label, multicenter Phase III clinical trial designed to compare the efficacy and safety of SHR-A2009 combined with aumolertinib versus aumolertinib monotherapy in treatment-naïve subjects with EGFR-mutated, locally advanced or metastat…
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Apr 22, 2026 16:00 UTC
-
Experimental gene injection offers hope for rare neurological disorder
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of MVX-220 gene therapy in children and adults with Angelman syndrome with UBE3A gene deletion, uniparental disomy, or imprinting center defect genotypes.
Phase: PHASE1, PHASE2 • Sponsor: MavriX Bio, LLC • Aim: Disease control
Last updated Apr 08, 2026 12:03 UTC
-
Double-Target cell therapy tested for stubborn blood cancer
Disease control Recruiting nowThis study is a single-center, open and dose-escalation clinical study to evaluate the safety, tolerability, PK/PD characteristics and preliminary efficacy of the investigational drug O\&D-001 injection in the treatment of relapsed or refractory multiple myeloma.
Phase: PHASE1 • Sponsor: O&D BioTech Group CO., Limited • Aim: Disease control
Last updated Apr 17, 2026 16:10 UTC
-
New cell therapy targets Hard-to-Treat lupus in groundbreaking trial
Disease control Recruiting nowThis is an open-label investigator-initiated trial (IIT) to assess the safety, efficacy, and PK(pharmacokinetic)/PD(pharmacodynamics ) of UB-VV410 in adult subjects with clinically active treatment-refractory SLE. The study population will include subjects with active LN (as defi…
Phase: PHASE1 • Sponsor: Nanjing IASO Biotechnology Co., Ltd. • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
Donor immune cells engineered to hunt lymphoma in new trial
Disease control Recruiting nowThis study involves patients with diffuse large B cell lymphoma (DLBCL), natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to collectively as lymphoma) whose disease has returned or not responded to treatment. Previous research combined antibod…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
AI predicts cancer comeback, guides Life-Saving treatment before it strikes
Disease control Recruiting nowThis study is for patients with early-stage liver cancer who are planning to have surgery. The goal of this research is to see if a personalized treatment plan, guided by a computer model (an artificial intelligence tool), can help prevent the cancer from coming back after surger…
Phase: PHASE1, PHASE2 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
New brain surgery technique aims to save lives and reduce disability after severe strokes
Disease control Recruiting nowThis is an phase III prospective, multi-center, open-label, randomized controlled trial (RCT) with blinded endpoint assessment. It plans to enroll 768 subjects with spontaneous supratentorial intracerebral hemorrhage, who will be randomly assigned in a 1:1 ratio to the investigat…
Phase: NA • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Apr 14, 2026 13:10 UTC